Increasing plasma calprotectin (S100A8/A9) is associated with 12-month mortality and unfavourable functional outcome in critically ill COVID-19 patients
Main finding · 12-month mortalityResult — go to the resultOdds ratio 2.10 95% CI 1.18–3.74Authors' conclusion
In critically ill COVID-19 patients, increasing calprotectin levels after admission to the ICU are associated with 12-month mortality and unfavourable functional outcome in survivors.
Study context
- Population
- Critically ill COVID-19 patients admitted to six intensive care units (ICUs) in Sweden, May 2020–May 2021
- Participants
- 498 patients · 6 ICUs
- Exposure
- Increasing vs non-increasing plasma calprotectin from ICU admission to day 7
- Outcome
- Mortality
- Follow-up
- 12 months
Methodological detailsmulticentre
- Multicentre
Main finding
12-month mortality
Odds ratio
2.10
95% CI 1.18–3.74
P = 0.012
Increasing vs non-increasing plasma calprotectin from ICU admission to day 7
OR 2.10 (95% CI 1.18–3.74); P = 0.012
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
Unfavourable functional outcome (Glasgow Outcome Scale Extended (GOSE) <5) · 3 months
| OR (95% CI) | P value | ||
|---|---|---|---|
| Increasing calprotectin from admission to day 7 | 2.53 (1.07–6.10) | P = 0.036 | |
| 0.10.31310Odds ratio (log scale) |
Use of invasive mechanical ventilation
| OR (95% CI) | P value | ||
|---|---|---|---|
| Increasing calprotectin from admission to day 7 | 2.23 (1.10–4.53) | P = 0.027 | |
| 0.20.5125Odds ratio (log scale) |
Use of continuous renal replacement therapy (CRRT)
| OR (95% CI) | P value | ||
|---|---|---|---|
| Increasing calprotectin from admission to day 7 | 2.07 (1.07–4.00) | P = 0.031 | |
| 0.20.5125Odds ratio (log scale) |
Prediction of 12-month mortality (ROC model: day 7 calprotectin + age)
- AUC (95% CI 0.74-0.84), p < 0.001
- 0.79
Prediction of unfavourable functional outcome (day 7 calprotectin alone) · 3 months
- AUC (95% CI 0.58-0.76), p < 0.001
- 0.67
Original publication
Increasing plasma calprotectin (S100A8/A9) is associated with 12-month mortality and unfavourable functional outcome in critically ill COVID-19 patients. J Intensive Care. Published 9 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →